Sequence-specific crosslinking agents for nucleic acids. Use of 6-bromo-5,5-dimethoxyhexanohydrazide for crosslinking cytidine to guanosine and crosslinking RNA to complementary sequences of DNA.

doi:10.1016/0022-2836(78)90032-3

Paper

DOI: 10.1016/0022-2836(78)90032-3

Sequence-specific crosslinking agents for nucleic acids. Use of 6-bromo-5,5-dimethoxyhexanohydrazide for crosslinking cytidine to guanosine and crosslinking RNA to complementary sequences of DNA.

Published Jun 25, 1978 · J. Summerton, P. Bartlett

Journal of molecular biology

Q1 SJR score

Citations

Influential Citations

Full textSemantic Scholar

Abstract

Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.

Study Snapshot

6-bromo-5,5-dimethoxyhexanohydrazide is a promising sequence-specific blocking agent for nucleic acids, potentially enabling systematic mapping and characterization of viral genomes.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

Full text analysis coming soon...

References

DOI: 10.1093/NAR/4.5.1609

Complementary addressed modification of yeast tRNA Val 1 with alkylating derivative of d(pC-G)-A. The positions of the alkylated nucleotides and the course of the alkylation in the complex.

Alkylation of yeast tRNA Val 1 with d(pC-G)-A, a benzylidene derivative, leads to the formation of beta-/N-methyl-N-(formylphenyl-17 amino/ethyl-tRNA Val 1), with a higher

1977·9citations·N. Grineva et al.·Nucleic acids research

Nucleic acids research

DOI: 10.1016/0022-2836(76)90149-2

Affinity labeling of specific regions of 23 S RNA by reaction of N-bromoacetyl-phenylalanyl-transfer RNA with Escherichia coli ribosomes.

Affinity labeling of 23 S ribosomal RNA supports models in which both ribosomal RNA and ribosomal protein contribute to the structure of the ribosome surrounding the peptidyl transferase center.

1976·30citations·J. Breitmeyer et al.·Journal of molecular biology

Journal of molecular biology

DOI: 10.1016/S0006-291X(75)80178-1

On the covalent binding of mRNA models to the part of the 16 S RNA which is located in the mRNA binding site of the 30 S ribosome.

The oligonucleotide U-U-(3H)-U-(nh 2 ) 2 U specifically binds to a guanosine in the mRNA binding site of the 30 S ribosome, with its binding inhibited by poly(U) but stimulated

1975·14citations·R. Wagner et al.·Biochemical and biophysical research communications

Biochemical and biophysical research communications

DOI: 10.1016/0014-5793(74)80501-6

Photoaffinity reagents for modification of aminoacyl‐tRNA synthetases

Photoreactive azido groups in ATP and tRNA analogs can be used for photoaffinity labeling of aminoacyl-tRNA synthetases, potentially enabling detailed investigation of enzyme active centers.

1974·28citations·V. Budker et al.·FEBS Letters

FEBS Letters

DOI: 10.1038/250514A0

Affinity labelling the acceptor site of the peptidyl transferase centre of the Escherichia coli ribosome

Two 50S proteins, L2 and L26-L27, are found in the peptidyl site of E. coli ribosomes, suggesting functional P site binding and dipeptide formation.

1974·28citations·D. Eilat et al.·Nature

Nature

Citations

DOI: 10.1021/acs.bioconjchem.8b00761

Bioconjugated Oligonucleotides: Recent Developments and Therapeutic Applications.

Bioconjugated oligonucleotides, combining various molecules, offer promising therapeutic applications for treating various diseases and offer potential for future clinical trials.

2019·158citations·S. Benizri et al.·Bioconjugate chemistry

Bioconjugate chemistry

DOI: 10.1016/j.bmc.2012.07.030

Novel photoresponsive cross-linking oligodeoxyribonucleotides having a caged α-chloroaldehyde.

Photoresponsive oligodeoxyribonucleotides with a caged -chloroaldehyde effectively create sequence-selective interstrand covalent bonds towards target nucleotides.

2012·10citations·A. Kobori et al.·Bioorganic & medicinal chemistry

Bioorganic & medicinal chemistry

DOI: 10.1002/jms.1762

Elucidating the higher-order structure of biopolymers by structural probing and mass spectrometry: MS3D.

MS-based technologies enable the determination of 3D structures of biopolymers, enabling the study of intractable substrates and their dynamics.

2010·42citations·D. Fabris et al.·Journal of mass spectrometry : JMS

Journal of mass spectrometry : JMS

DOI: 10.2174/156802607780487740

Morpholino, siRNA, and S-DNA compared: impact of structure and mechanism of action on off-target effects and sequence specificity.

Morpholinos achieve high sequence specificity and minimal off-target effects, making them ideal for developing embryo studies.

2007·234citations·J. Summerton·Current topics in medicinal chemistry

Current topics in medicinal chemistry

DOI: 10.1074/jbc.M313603200

A Natively Unfolded Toxin Domain Uses Its Receptor as a Folding Template*

The colicin N translocation domain folds cooperatively using its receptor as a folding template, converting the disordered structure into a cooperatively folded domain without altering the TolA-(296-421) structure.

2004·26citations·G. Anderluh et al.·Journal of Biological Chemistry

Journal of Biological Chemistry

DOI: 10.1016/S0163-7258(03)00053-6

Antisense therapeutics: from theory to clinical practice.

Antisense therapeutics have rapidly progressed past Phase I in clinical trials, with cancer being the main focus, and this review highlights the current trials and potential targets for future antisense molecules.

2003·105citations·K. Pirollo et al.·Pharmacology & therapeutics

Pharmacology & therapeutics

DOI: 10.1074/JBC.M300411200

Concerted Folding and Binding of a Flexible Colicin Domain to Its Periplasmic Receptor TolA*

The colicin N translocation domain undergoes concerted binding and folding, switching from a disordered state to an ordered state, resulting in molecular recognition.

2003·30citations·G. Anderluh et al.·Journal of Biological Chemistry

Journal of Biological Chemistry

DOI: 10.1016/S0167-4781(99)00148-7

Molecular mechanisms of action of antisense drugs.

Antisense drugs can target various RNA structures, with a growing repertoire of potential mechanisms and modified oligonucleotides to match to the desired mechanism.

1999·364citations·S. Crooke·Biochimica et biophysica acta

Biochimica et biophysica acta

DOI: 10.1089/OLI.1.1997.7.187

Morpholino antisense oligomers: design, preparation, and properties.

Morpholino antisense oligos offer high and predictable activity in cells, solving sequence specificity issues and offering low production costs for potential therapeutic applications.

1997·1070citations·J. Summerton et al.·Antisense & nucleic acid drug development

Antisense & nucleic acid drug development